Gastroenterology
Volume 134, Issue 4 , Pages 929-936 , April 2008

Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease

  • Murat Toruner

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Edward V. Loftus Jr

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • W. Scott Harmsen

      Affiliations

    • Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Alan R. Zinsmeister

      Affiliations

    • Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Robert Orenstein

      Affiliations

    • Division of Infectious Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • William J. Sandborn

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Jean–Frederic Colombel

      Affiliations

    • Department of Hepato-Gastroenterology, Centre Hospitalier Regional Universitaire De Lille, France
    • ,
  • Laurence J. Egan

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • Department of Pharmacology & Therapeutics, National University of Ireland, Galway, Ireland
    • Corresponding Author InformationAddress requests for reprints to: Laurence J. Egan, MD, Department of Pharmacology and Therapeutics, University College Hospital, Galway, Ireland. fax: (353)91495572.

Received 24 June 2007 ,Accepted 4 January 2008.

References 

  1. Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am. 2001;15:423–432viii
  2. Arts J, D’Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10:73–78
  3. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31
  4. Hamlin PJ, Shah MN, Scott N, et al. Systemic cytomegalovirus infection complicating ulcerative colitis: a case report and review of the literature. Postgrad Med J. 2004;80:233–235
  5. Jess T, Winther KV, Munkholm P, et al. Mortality and causes of death in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology. 2002;122:1808–1814
  6. Winther KV, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology. 2003;125:1576–1582
  7. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–630
  8. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease (North American Crohn’s Study Group Investigators). N Engl J Med. 2000;342:1627–1632
  9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549
  10. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476
  11. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885
  12. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333591
  13. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65
  14. Hammer SM. Clinical practice (Management of newly diagnosed HIV infection). N Engl J Med. 2005;353:1702–1710
  15. Guerrant RL, Lima AA, Davidson F. Micronutrients and infection: interactions and implications with enteric and other infections and future priorities. J Infect Dis. 2000;182(Suppl 1):S134–S138
  16. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–237
  17. Weiler CR, Bankers-Fulbright JL. Common variable immunodeficiency: test indications and interpretations. Mayo Clin Proc. 2005;80:1187–1200
  18. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet. 2003;361:1545–1551
  19. Murphy TF, Sethi S, Niederman MS. The role of bacteria in exacerbations of COPD (A constructive view). Chest. 2000;118:204–209
  20. Picazo JJ. Management of the febrile neutropenic patient: a consensus conference. Clin Infect Dis. 2004;39(Suppl 1):S1–S6
  21. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483–1490
  22. Disanti W, Rajapakse RO, Korelitz BI, et al. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1025–1029
  23. Dayharsh GA, Loftus EV, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72–77
  24. Ang YS, Farrell RJ. Risk of lymphoma: inflammatory bowel disease and immunomodulators. Gut. 2006;55:580–581
  25. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002;16:1225–1232
  26. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–1125
  27. Loftus EV, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95:2308–2312
  28. Loftus EV, Sandborn WJ. Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology. 2001;121:1239–1242
  29. Reddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006;35:837–855
  30. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54:1075–1086
  31. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–1104
  32. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133–1145
  33. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125:320–327
  34. Colombel JF, Loftus EV, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878–883
  35. Aberra FN, Lichtenstein GR. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:685–695

PII: S0016-5085(08)00051-6

doi: 10.1053/j.gastro.2008.01.012

Gastroenterology
Volume 134, Issue 4 , Pages 929-936 , April 2008

Article Tools